Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain Clinical Trial

Official title:
A Study of the Efficacy and Safety of 8 Mg Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Status Terminated

Clinical Trial Summary

The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone Hydrochloride Extended-Release.

Clinical Trial Description

The primary efficacy objective of this study is to compare the time to emergence of inadequate analgesia of 8 mg Hydromorphone Hydrochloride Extended-Release taken once every 24 hours versus placebo in the treatment of patients with persistent pain who require an opioid medication for control of their pain. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Non-Malignant Pain

Clinical Trial Details

NCT number	NCT00365898
Study type	Interventional
Source	Purdue Pharma LP
Contact
Status	Terminated
Phase	Phase 3
Start date	July 2005
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01888146` - Pain Program for Active Coping & Training	N/A
Completed	`NCT00312195` - Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain	Phase 3
Completed	`NCT03761277` - Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain	Phase 4
Completed	`NCT02113592` - Pain Program for Active Coping & Training	N/A